<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02015416</url>
  </required_header>
  <id_info>
    <org_study_id>IDC-G305-2013-001</org_study_id>
    <nct_id>NCT02015416</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune Design</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical
      safety and immune response of IDC-G305 when injected intramuscularly in patients with
      unresectable or metastatic cancer.  IDC-G305 is an immunotherapy consisting of recombinant
      NY-ESO-1 antigen and the adjuvant, GLA-SE.  The goal is for IDC-G305 to stimulate the body's
      immune system to fight the spread and growth of cancer for patients whose tumors include the
      NY-ESO-1 protein.  Patients with melanoma, ovarian, renal cell or non-small cell lung cancer
      may be considered for the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open label, multicenter, multiple ascending dose trial of IDC-G305
      administered by intramuscular injection in a 3+3 sequential dose escalation design.
      IDC-G305 is an immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant,
      GLA-SE.   Patients with unresectable, relapsed or metastatic cancer but with low disease
      burden and indolent disease course may be considered for the trial.  Tumors must express the
      NY-ESO-1 gene signature and tumor types that will be studied are: melanoma, ovarian,
      sarcoma,non-small cell lung  and breast cancer.

      Each of three dose level cohorts will be treated contingent upon absence of dose limiting
      toxicity (DLT) and acceptable safety data for the preceding cohort.   Initially, three
      patients will be scheduled to receive IDC-G305 in each dose level cohort. Dose escalation
      will be contingent upon the assessment of safety data obtained during the initial
      injections.

      Patients will be evaluated at baseline and at regular intervals for safety and immune
      response.  Both cellular and humoral immunogenicity will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 1 year after last vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety and tolerability of multiple ascending doses of intramuscular (IM) IDC-G305</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary objective is to evaluate the humoral and cellular immunogenicity of multiple ascending doses of intramuscularly administered IDC-G305</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IDC-G305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NY-ESO-1 recombinant protein together with GLA-SE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IDC-G305</intervention_name>
    <description>NY-ESO-1 recombinant protein together with GLA-SE</description>
    <arm_group_label>IDC-G305</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small
             cell lung cancer (NSCLC)

          -  Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden.
             Disease may or may not be measurable and should not be rapidly progressive.
             Inadequate response, relapse and/or unacceptable toxicity with one or more prior
             systemic, surgical, or radiation cancer therapies, except patients with NSCLC and
             breast cancer who must have experienced an inadequate response and/or unacceptable
             toxicity with two or more prior systemic, surgical, or radiation cancer therapies.

          -  Cancer expresses NY-ESO-1

          -  ≥ 18 years of age

          -  Life expectancy of ≥ 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  ECG without evidence of clinically significant arrhythmia or ischemia

          -  Negative pregnancy test for females of childbearing potential

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Vaccine or other therapy directed against NY-ESO-1 at any time in the past and any
             investigational therapy within three weeks prior to IDC-G305 dosing

          -  Significant immunosuppression

          -  Cancer chemotherapy, G-CSF or GM-CSF within three weeks prior to the first study
             treatment

          -  Significant autoimmune disease

          -  Myocardial infarction within six months of treatment, active cardiac ischemia or
             Grade III or IV heart failure

          -  Inadequate hematology or chemistry profiles

          -  History of other cancer within three years

          -  Active, concurrent or recent infection, including tuberculosis, hepatitis B,
             hepatitis C or HIV

          -  Uveal melanoma

          -  Brain metastases considered unstable
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunle Odunsi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Immune Design</last_name>
    <phone>650-887-6703</phone>
    <email>ClinicalTrials@ImmuneDesign.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Downhour, RN</last_name>
      <phone>480-323-1357</phone>
      <email>mdownhour@shc.org</email>
    </contact>
    <investigator>
      <last_name>Daniel D Von Hoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Burke</last_name>
      <phone>813-745-4616</phone>
      <email>Nancy.burke@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Amit Mahipal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarice Zuccaro</last_name>
      <phone>313-576-9375</phone>
      <email>zuccaroc@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Shelly Seward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francine Siedlecki, RN</last_name>
      <phone>716-845-1439</phone>
      <email>Francine.Siedlecki@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Kunle Odunsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Breast cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
